[Pubmed] The treatment with or without prednisolone in adults aged 70 years with myasthenia gravis: a retrospective co

[RSS-Bot]

Front Neurol. 2026 Jul 29;17:1853517. doi: 10.3389/fneur.2026.1853517. eCollection 2026.

ABSTRACT

INTRODUCTION: This retrospective, single-center cohort study aimed to compare clinical outcomes, including time to minimal manifestations (MM)-defined as the absence of functional limitations from MG symptoms in daily activities, even with mild muscle weakness on examination-or better status, between patients aged ≥70 years with MG treated with PSL alone or with calcineurin inhibitors (CNIs), and those treated with CNI alone.

METHODS: Twelve patients with acetylcholine receptor antibody (AChR-Ab)-positive MG aged ≥70 years were included (the PSL group, n = 7; the CNIs group, n = 5). Changes in the MG Activities of Daily Living scale (MG-ADL) and Quantitative MG (QMG) scores from admission to discharge were evaluated using least-squares mean estimates. Longitudinal changes in AChR-Ab titers over one year were analyzed using a mixed-effects model for repeated measures. The time to MM was assessed using Kaplan-Meier analysis.

RESULTS: The MG-ADL scores improved in both groups, with a greater change in the PSL group. QMG scores improved in the PSL group, while no significant change was observed in the CNIs group; however, discharge QMG scores and changes did not differ significantly between the groups. No differences were observed in AChR-Ab titers or the cumulative incidence of MM. All patients in both groups achieved MM or better status within one year.

DISCUSSION: In this cohort of patients aged ≥70 years with MG, favorable outcomes were observed, regardless of PSL use. These findings highlight the clinical heterogeneity among older patients with MG and underscore the need for individualized treatment approaches.

PMID:42591132 | PMC:PMC13461386 | DOI:10.3389/fneur.2026.1853517


Source: https://pubmed.ncbi.nlm.nih.gov/4259113 ... 9&v=2.20.1